Menu
Search
|

Menu

Close
X

Pain Therapeutics Inc PTIE.OQ (NASDAQ Stock Exchange Capital Market)

1.08 USD
-0.05 (-4.42%)
As of 2:29 AM IST
chart
Previous Close 1.13
Open 1.12
Volume 25,920
3m Avg Volume 330,530
Today’s High 1.12
Today’s Low 1.08
52 Week High 12.80
52 Week Low 0.81
Shares Outstanding (mil) 6.60
Market Capitalization (mil) 28.03
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.684
FY17
-1.822
FY16
-2.280
FY15
-2.159
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
2.11
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-71.40
15.05
Return on Equity (TTM)
vs sector
-71.40
16.62

EXECUTIVE LEADERSHIP

Remi Barbier
Chairman of the Board, President, Chief Executive Officer, Since 1998
Salary: $875,000.00
Bonus: --
Nadav Friedmann
Chief Medical and Operating Officer, Director, Since 2004
Salary: $320,000.00
Bonus: --
Robert Gussin
Independent Director, Since 2003
Salary: --
Bonus: --
Michael O' Donnell
Independent Director, Since
Salary: --
Bonus: --
Saira Ramasastry
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7801 N Capital of Texas Hwy Ste
AUSTIN   TX   78731-1192

Phone: +1512.5012444
Site:

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

SPONSORED STORIES